AMAG Pharmaceuticals Inc
$
10.34
-0.44 (-4.08%)
| Volume: | 756,548 | Avg Vol (1m): | 589,456 |
| Market Cap $: | 349.15 Mil | Enterprise Value $: | 348.22 Mil |
| P/E (TTM): | 0.00 | P/B: | 0.58 |
| Earnings Power Value | 12.04 |
| Net Current Asset Value | -1.1 |
| Tangible Book | -0.61 |
| Projected FCF | 40.01 |
| Median P/S Value | 65.64 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 5/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 1.00 |
Cash-To-Debt ranked
lower than
88.22%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
AMAG:
1
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.29, Med: 10000, Max: 10000
Current: 1
|
| Equity-to-Asset | 0.57 |
Equity-to-Asset ranked
lower than
78.90%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
AMAG:
0.57
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: 0.33, Med: 0.78, Max: 0.99
Current: 0.57
|
| Debt-to-Equity | 0.43 |
Debt-to-Equity ranked
lower than
83.80%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
AMAG:
0.43
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: 0.37, Med: 0.94, Max: 1.17
Current: 0.43
|
| Debt-to-EBITDA | -10.12 |
Debt-to-EBITDA ranked
lower than
100.00%
of
196
companies
in the
Biotechnology
industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
AMAG:
-10.12
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -4.7, Med: 5.24, Max: 114.16
Current: -10.12
|
| Piotroski F-Score | 6 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | -0.18 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.95 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC -24.01%
WACC 6.69%
| ||
Profitability & Growth : 6/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -36.16 |
Operating Margin ranked
higher than
71.97%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
AMAG:
-36.16
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -570.13, Med: -11.67, Max: 30.26
Current: -36.16
|
| Net Margin % | -30.90 |
Net Margin ranked
higher than
60.23%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
AMAG:
-30.9
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -543.43, Med: -16.75, Max: 109.19
Current: -30.9
|
| ROE % | -18.60 |
ROE ranked
higher than
59.05%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
AMAG:
-18.6
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -52.39, Med: -9.02, Max: 42.96
Current: -18.6
|
| ROA % | -9.37 |
ROA ranked
higher than
69.65%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
AMAG:
-9.37
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -44.82, Med: -5.33, Max: 16.42
Current: -9.37
|
| ROC (Joel Greenblatt) % | -1261.49 |
ROC (Joel Greenblatt) ranked
lower than
61.00%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
AMAG:
-1261.49
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -1928.22, Med: -488.06, Max: 481.05
Current: -1261.49
|
| 3-Year Total Revenue Growth Rate | 4.30 |
3-Year Revenue Growth Rate ranked
higher than
88.94%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
AMAG:
5.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -78.7, Med: 5.4, Max: 278.5
Current: 5.2
|
| 3-Year Total EBITDA Growth Rate | -16.50 |
3-Year EBITDA Growth Rate ranked
lower than
100.00%
of
802
companies
in the
Biotechnology
industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
AMAG:
-15.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
| N/A |
» AMAG's 30-Y Financials
Financials (Next Earnings Date: 2019-08-02)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:AMAG
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | NAS:TCRR NAS:ALBO NAS:KALV XTER:FYB NAS:SVRA NAS:ABEO TSX:TH NAS:PHAS XKRX:299660 SZSE:300404 ROCO:6712 NAS:APM SZSE:300049 SZSE:002286 NAS:RIGL XKRX:144510 XKRX:084110 XKRX:102940 TSXV:EMH SZSE:002868 |
| Traded in other countries | AMU.Germany |
| Address | 1100 Winter Street, Waltham, MA, USA, 02451 |
| Founded in 1981, AMAG Pharmaceuticals uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 0.58 |
PB Ratio ranked
higher than
88.88%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
AMAG:
0.58
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 0.56, Med: 1.95, Max: 6.02
Current: 0.58
|
| PS Ratio | 0.82 |
PS Ratio ranked
higher than
92.15%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
AMAG:
0.82
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 0.82, Med: 5.23, Max: 505.93
Current: 0.82
|
| EV-to-EBIT | -2.43 |
EV-to-EBIT ranked
lower than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
AMAG:
-2.43
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -787.3, Med: -3.65, Max: 87.5
Current: -2.43
|
| EV-to-EBITDA | -13.26 |
EV-to-EBITDA ranked
lower than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
AMAG:
-13.26
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -180.4, Med: -4.45, Max: 479.9
Current: -13.26
|
| EV-to-Revenue | 0.81 |
EV-to-Revenue ranked
higher than
88.85%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
AMAG:
0.81
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 0.3, Med: 2.9, Max: 435.3
Current: 0.81
|
| Current Ratio | 2.30 |
Current Ratio ranked
lower than
75.05%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
AMAG:
2.3
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1.51, Med: 8.93, Max: 62.43
Current: 2.3
|
| Quick Ratio | 2.13 |
Quick Ratio ranked
lower than
72.63%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
AMAG:
2.13
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 1.4, Med: 8.45, Max: 61
Current: 2.13
|
| Days Inventory | 62.77 |
Days Inventory ranked
higher than
76.72%
of
481
companies
in the
Biotechnology
industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
AMAG:
62.77
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 51.68, Med: 403.83, Max: 1713.48
Current: 62.77
|
| Days Sales Outstanding | 70.34 |
Days Sales Outstanding ranked
higher than
52.10%
of
668
companies
in the
Biotechnology
industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
AMAG:
70.34
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 27.4, Med: 62.68, Max: 581.14
Current: 70.34
|
| Days Payable | 46.11 |
Days Payable ranked
lower than
83.02%
of
536
companies
in the
Biotechnology
industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
AMAG:
46.11
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 13.96, Med: 85.23, Max: 1957.24
Current: 46.11
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | 0.10 |
3-Year Share Buyback Rate ranked
higher than
60.44%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
AMAG:
0.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -28.7, Med: -6.3, Max: 0.7
Current: 0.1
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 0.26 |
Price-to-Intrinsic-Value-Projected-FCF ranked
higher than
96.89%
of
193
companies
in the
Biotechnology
industry.
Industry Max: 117, Med: 3.12, Min: 0.09
AMAG:
0.26
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.29, Med: 3.71, Max: 96.83
Current: 0.26
|
| Price-to-Median-PS-Value | 0.16 |
Price-to-Median-PS-Value ranked
higher than
89.38%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
AMAG:
0.16
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.17, Med: 1.89, Max: 277.17
Current: 0.16
|
| Earnings Yield (Joel Greenblatt) % | -41.15 |
Earnings Yield (Greenblatt) ranked
lower than
70.49%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
AMAG:
-41.15
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -458.4, Med: -15.4, Max: 7.5
Current: -41.15
|
More Statistics
| Revenue (TTM) (Mil) $ | 432.42 |
| EPS (TTM) $ | -3.87 |
| Beta | 0.05 |
| Volatility % | 49.59 |
| 52-Week Range $ | 10.08 - 26.1 |
| Shares Outstanding (Mil) | 33.77 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 6 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |